↓ Skip to main content

Axon growth inhibition by RhoA/ROCK in the central nervous system

Overview of attention for article published in Frontiers in Neuroscience, October 2014
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (87th percentile)
  • High Attention Score compared to outputs of the same age and source (81st percentile)

Mentioned by

twitter
9 X users
patent
2 patents

Readers on

mendeley
238 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Axon growth inhibition by RhoA/ROCK in the central nervous system
Published in
Frontiers in Neuroscience, October 2014
DOI 10.3389/fnins.2014.00338
Pubmed ID
Authors

Yuki Fujita, Toshihide Yamashita

Abstract

Rho kinase (ROCK) is a serine/threonine kinase and a downstream target of the small GTPase Rho. The RhoA/ROCK pathway is associated with various neuronal functions such as migration, dendrite development, and axonal extension. Evidence from animal studies reveals that RhoA/ROCK signaling is involved in various central nervous system (CNS) diseases, including optic nerve and spinal cord injuries, stroke, and neurodegenerative diseases. Given that RhoA/ROCK plays a critical role in the pathophysiology of CNS diseases, the development of therapeutic agents targeting this pathway is expected to contribute to the treatment of CNS diseases. The RhoA/ROCK pathway mediates the effects of myelin-associated axon growth inhibitors-Nogo, myelin-associated glycoprotein (MAG), oligodendrocyte-myelin glycoprotein (OMgp), and repulsive guidance molecule (RGM). Blocking RhoA/ROCK signaling can reverse the inhibitory effects of these molecules on axon outgrowth, and promotes axonal sprouting and functional recovery in animal models of CNS injury. To date, several RhoA/ROCK inhibitors have been under development or in clinical trials as therapeutic agents for neurological disorders. In this review, we focus on the RhoA/ROCK signaling pathway in neurological disorders. We also discuss the potential therapeutic approaches of RhoA/ROCK inhibitors for various neurological disorders.

X Demographics

X Demographics

The data shown below were collected from the profiles of 9 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 238 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 1 <1%
United States 1 <1%
Germany 1 <1%
Brazil 1 <1%
Unknown 234 98%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 52 22%
Student > Bachelor 38 16%
Student > Master 32 13%
Researcher 23 10%
Student > Doctoral Student 19 8%
Other 31 13%
Unknown 43 18%
Readers by discipline Count As %
Neuroscience 58 24%
Agricultural and Biological Sciences 54 23%
Biochemistry, Genetics and Molecular Biology 29 12%
Medicine and Dentistry 22 9%
Engineering 8 3%
Other 17 7%
Unknown 50 21%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 12. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 October 2021.
All research outputs
#3,136,156
of 25,515,042 outputs
Outputs from Frontiers in Neuroscience
#2,195
of 11,594 outputs
Outputs of similar age
#34,914
of 273,453 outputs
Outputs of similar age from Frontiers in Neuroscience
#22
of 116 outputs
Altmetric has tracked 25,515,042 research outputs across all sources so far. Compared to these this one has done well and is in the 87th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 11,594 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.0. This one has done well, scoring higher than 80% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 273,453 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 87% of its contemporaries.
We're also able to compare this research output to 116 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 81% of its contemporaries.